Topic: One-in-A-Million: Applications of Duplex Sequencing
Dr. Anup Madan is a Vice President, Strategic Alliance, of TwinStrand Biosciences. His research interests lie in studying somatic evolution and the genomic processes that occur on the continuum between “normal”, preneoplastic and cancer, and applying this to knowledge to clinical medicine. TwinStrand Biosciences develops ultrasensitive Duplex Sequencing-based assays for early detection of cancer, residual disease monitoring and genotoxin assessment. Duplex Sequencing enables an unprecedented level of NGS accuracy, with error rates below one-in-ten-million. The technology is ideally suited to early detection of cancer, among other high sensitivity fields. Here we illustrate clinically-relevant case studies where such accuracy is critical.

Prior to joining TwinStrand Biosciences, Dr Madan was Executive Director at Covance and led a group that offered Genomics solution to various pharmaceutical companies for clinical trials. Some of the biomarkers identified by his group are being developed as companion/complementary diagnostics for various oncology drugs. He continues to collaborate with both academic and pharmaceutical groups and had published in various well reputed journals.

Topic: Low-pass sequencing for cost-effective and scalable genomics applications
Joe is a statistical geneticist who has published scientific papers in the most selective scientific journals like Nature, Science, Nature Genetics, and PNAS. Prior to founding Gencove, he was a professor at New York Genome Center and Columbia University, and he holds a PhD in Human Genetics from the University of Chicago.